Siddhartha Ganguly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Siddhartha Ganguly has a total of 641 co-authors. Here are the top co-authors by number of shared publications:
- Joseph P. McGuirk
Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States; The Mikael Rayaan Foundation Global Research Training Institute (MRF GRTI), Kansas City, KS, United States; U.S Myeloma Innovations Research Collaborative, Kansas City, KS, United States
13 shared publications - Sai Ravi Pingali
Neal Cancer Center, Houston Methodist Hospital, Houston, USA
12 shared publications - Alan Hodges
Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas
11 shared publications - Brooke Prinzing
Department of Bone Marrow Transplantation & Cellular Therapy, St Jude Children's Research Hospital, Memphis, Tennessee
11 shared publications - Fumiko Nakatsu
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
11 shared publications - Hui-Ming Chen
Center for Immunotherapy, Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas
11 shared publications
Latest Publications
- 27 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1491.e1-1491.e15
Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
- 27 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1491.e1-1491.e15
Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1. LILRB1-4 surface expression in AML patient samples from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Percent LILRB1-4 positive cells in human AML PBMC. Gated on viable CD33+ cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1. LILRB1-4 surface expression in AML patient samples from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Percent LILRB1-4 positive cells in human AML PBMC. Gated on viable CD33+ cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2. Ingenuity Pathway Analysis of LILRB3 antibody treated U937 cells from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Pathway analysis of LILRB3 antibody treated U937 cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2. Ingenuity Pathway Analysis of LILRB3 antibody treated U937 cells from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Pathway analysis of LILRB3 antibody treated U937 cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3. CBC+CMP from LILRB3 CAR T adoptively transferred LILRB3 transgenic mice from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Complete Blood Counts and Metabolic Panel for LILRB3 specific CAR adoptively transferred LILRB3 transgenic naive mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3. CBC+CMP from LILRB3 CAR T adoptively transferred LILRB3 transgenic mice from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Complete Blood Counts and Metabolic Panel for LILRB3 specific CAR adoptively transferred LILRB3 transgenic naive mice.
- 28 December 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (5) , 580.e1-580.e18
Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults With Acute Myeloid Leukemia: A CIBMTR Report
- 28 December 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (5) , 580.e1-580.e18
Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults With Acute Myeloid Leukemia: A CIBMTR Report
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2. Ingenuity Pathway Analysis of LILRB3 antibody treated U937 cells from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Pathway analysis of LILRB3 antibody treated U937 cells.
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2. Ingenuity Pathway Analysis of LILRB3 antibody treated U937 cells from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Pathway analysis of LILRB3 antibody treated U937 cells.
- Open Access
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1. LILRB1-4 surface expression in AML patient samples from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Percent LILRB1-4 positive cells in human AML PBMC. Gated on viable CD33+ cells
- 9 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1. LILRB1-4 surface expression in AML patient samples from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
Percent LILRB1-4 positive cells in human AML PBMC. Gated on viable CD33+ cells